Recombinant KRT17 anticorps

N° du produit ABIN7881373

L’anticorps anti-KRT17 Monoclonal Lapin est utilisé pour la détection de KRT17 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour Recombinant KRT17 anticorps (ABIN7881373)

Antigène: KRT17 (Keratin 17 (KRT17))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp KRT17 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: KRT17-8346R

Détail du produit anti-KRT17 anticorps

Fonction: Recombinant Keratin 17 Antibody / Cytokeratin 17

Purification: Protein A/G affinity

Immunogène: A recombinant fragment of human KRT17 protein was used as the immunogen for the recombinant Keratin 17 antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the recombinant Keratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the recombinant Keratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur KRT17

Antigène: KRT17 (Keratin 17 (KRT17))

Autre désignation: Keratin 17

Sujet: Cytokeratin 17 is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course.

UniProt: Q04695